INVESTORS

Stakeholders

Our Stakeholders

We collaborate with experts, investors and service providers to bring transformational treatments to patients sooner.

A. Stakeholder Management

Stakeholders of the company include employees, shareholders, board members, investors, strategic partners, suppliers, and regulatory authorities.

Employees:

The company treats employees with integrity and has implemented various measures to ensure employees’ welfare, including education training programs and performance development plans to protect employees’ rights and interests and facilitate employees’ career development. With smooth communication channels between employees and supervisors, the current labour relationship is good.

Shareholders and Investors:

The company has a spokesperson and entrusts a professional stock transfer agency to deal with shareholder-related issues. In addition, to make the public investors understand the company’s operating conditions, the company discloses relevant information in the public information observatory in accordance with regulations.

Board Members:

The directors have the right to avoid voting on proposals with which they have conflicts of interest. They follow the principle of abstention from voting on the proposals. The company also purchased liability insurance for directors starting in 2022.

The directors and independent directors of the company have relevant professional knowledge. In order to strengthen the functions of the board, directors and independent directors participate in relevant professional courses each year.

Strategic Partners:

The business development strategy of the company is focusing on finding strategic partners to out license assets for further development. The company also continuously monitors the market by paying attention to the status of marketed and developing products to understand the competitive landscape and to seek the best strategic partners. With current strategic partners, the company also manages the alliance by assisting in research and development to help our partners race for market approval.

Suppliers:

Since new drug development is the main business of the company, and the products are still in the research and development stage, there are no commercial customers.

The company also has no lab space, production plants, or equipment. The virtual operation model is mainly executed by outsourcing and managed by project management. Through a careful selection process, the company outsources the customized processes to qualified suppliers that comply with cGMP standards. Therefore, the company has established a supplier management policy. Before dealing with suppliers, we will conduct appropriate assessments according to our needs and regulatory requirements, and select manufacturers or service providers with no bad track records. All commercial activities between the company and major suppliers are protected by signed contracts. No major suppliers have been found with violations of laws regarding environmental protection, occupational safety and health, labour rights, product liability, etc.

Contacts:

The company has spokespersons and deputy spokespersons as communication channels for stakeholders. If necessary, stakeholders can contact the company by telephone, letter, fax, and e-mail at any time. For communication through email, please include your questions, your name, phone number, email, and/or your company for quicker response.

BRIM Investor Relations

Spokesperson: Erin Chang
Deputy spokesperson: Ben Wu
Phone: +886-2-2659-8586
Fax: +886-2-2659-8779
Email: ir@brimbiotech.com

B. Integrity Management

The company conducts business based on the principles of fairness, honesty, trustworthiness, and transparency. To implement the integrity management policy and actively prevent dishonest behaviors, the board of directors has passed the “Integrity Management Operating Procedures and Behavior Guidelines” to encourage internal and external personnel to report dishonest behavior or misconduct.

C. Whistle-blower Form Submission

The company establishes and announces the internal independent reporting email on the company website and provides a form for the internal and external whistle-blowers to report any misconduct of the Company.

The whistle-blower should provide at least the following information:

  1. The name of the whistle-blower can be optional. The address, telephone number, and e-mail address of the whistle-blower who can be contacted are required.
  2. The name of the accused person or other information sufficient to identify the accused person’s identity.
  3. Specific facts available for investigation.

The relevant personnel of the company handling the whistle-blowing situation shall deal with it in accordance with this operating procedure, and shall declare in writing that the identity of the whistle-blower and the content of the issue shall be kept confidential.

BRIM has set up a reporting mailbox. If you wish to report any dishonest behavior or misconduct by the company or personnel, please send the information and attach specific evidence through the following e-mail: integrity@brimbiotech.com

D. Advisor Contacts

Stock Transfer Agency

SinoPac Securities
3F, No. 17, Bo’ai Rd,
Zhongzheng District,
Taipei City, 100
Taiwan


Phone: +886-2-2381-6288
Fax: +886-2-2659-8779
Web: www.sinotrade.com.tw/stocktransfer

BRIM Investor Relations

Spokesperson: Erin Chang
Deputy spokesperson: Ben Wu

Phone: +886-2-2659-8586
Fax: +886-2-2659-8779
Email: ir@brimbiotech.com

Interested in becoming an investor in BRIM Biotechnology?

Please get in touch via the button below

Download BRIM's Corporate Overview